An Ayurvedic Clinical study to evaluate the efficacy of different forms and doses of CURCUMIN for Rheumatoid Arthritis patients

INTERVENTION: Intervention1: Curcumin 500 mg, Curcumin 250 mg, white curcumin: oral route of administration, One capsule per day Control Intervention1: Active :CURCUMIN Comparator:Plcebo: All enrolled 48 subjects will be divided into four groups of 12 each. Each group will receive either treatment A, B C or D containing the same active ingredient CONDITION: RHEUMATOID ARTHRITIS PATIENTS PRIMARY OUTCOME: To evaluate the comparative efficacy of curcumin (low & high dose), white curcumin with that of a placebo‐‐‐‐‐‐Timepoint: Screening â?? (Day ‐ 7) ; Baseline visit â?? (Day 0) ; Visit 2 (Day 30) ; Visit 3 (Day 60) ; Visit 4 (Day 90) SECONDARY OUTCOME: a. To assess the safety & tolerability of active products ; b. To assess changes in various biomarkers during the study period among all the study group subjects. ; ‐‐‐‐‐‐Timepoint: Day 0 ; Day 30 ; Day 60 ; Day 90 INCLUSION CRITERIA: i.Patients with active RA for at least one (1) year, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis. ii.Receiving treatment on an outpatient basis. iii.Active disease at the time of screening.